Italy Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Italy Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Italy Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View : The rising demand for medicines for the treatment of cardiovascular diseases, gastric conditions, the nervous system and the respiratory system (the therapeutic areas that recorded the highest expenditure in 2015) and the government's aim in ensuring its population continues to access these medicines, will lead to complex pricing and reimbursement discussions, placing downward pressures on drugmaker revenue streams. Despite a long-term decline in the public expenditure of medicines, the implementation of further austerity measures targeting both the SSN and the sector is inevitable.

Headline Expenditure Projections

  • Pharmaceuticals: EUR28.93bn (USD32.08bn) in 2015 to EUR29.16bn (USD31.20bn) in 2016; +0.8% in local currency terms and -2.8% in US dollar terms.

  • Healthcare: EUR150.50bn (USD166.92bn) in 2015 to EUR151.88bn (USD162.51bn) in 2016; +0.9% in local currency terms and -2.6% in US dollar terms.

Headline Pharmaceuticals & Healthcare Forecasts (Italy 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 35.332 32.080 31.198 30.903 30.347 30.100 30.468
Pharmaceutical sales, % of GDP 1.65 1.77 1.77 1.74 1.72 1.70 1.68
Pharmaceutical sales, % of health expenditure 17.8 19.2 19.2 19.2 19.2 19.1 19.1
Health spending, USDbn 198.013 166.917 162.507 161.112 158.412 157.397 159.781

Risk/Reward Index

In our Pharmaceuticals and Healthcare Risk/Reward Index for Q117, Italy comes in 11th place out of the 15 markets surveyed in Western Europe, above Ireland and Portugal and below the Netherlands and Spain. Despite being a large market, Italy is characterised by low levels of annual growth, largely due to of widespread price cuts, resulting in the market scoring a below average rating of 66.3 out of a total of 100.

Latest Updates

  • In October 2016, AIFA reported that drugmakers including Roche, Gilead and Janssen-Cilag will have to pay back rebates of EUR1.49bn for an overspend on medicines during the 2013-2015 time period.

  • In October 2016, it was reported that the Italian Market Competition Authority (AGCM) is fining the multinational South African pharmaceutical company Aspen nearly EUR5.2mn on following its finding that Aspen abused its dominance to artificially inflate the price of four of its cancer drugs.

  • In 6M16, pharmaceutical expenditure by the SSN fell by 4.7% to EUR4.28bn (USD3.92bn).

BMI Economic View

Weaker external demand, rising political risks and a crippled banking sector will stifle Italy's nascent economic recovery. Subdued growth will impede fiscal consolidation efforts, leaving the economy highly vulnerable to confidence shocks and dependent on the implicit backstop of the European Central Bank.

BMI Political View

Italy's upcoming constitutional referendum poses the most salient short-term political risk, given its potential to topple the reformist government of Prime Minister Matteo Renzi. However, no matter the outcome, medium-term risks remain elevated due to a stagnant economy and the continued rise in popularity of the anti-establishment and eurosceptic 5-Star Movement, which could conceivably achieve a one-party government in 2018.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Italy 2014-2020)
7
SWOT
9
Industry Forecast
10
Pharmaceutical Market Forecast
10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Italy 2012-2020)
12
Healthcare Market Forecast
13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Italy 2012-2020)
15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Italy 2012-2020)
15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Italy 2012-2020)
16
Prescription Drugs Market Forecast
17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Italy 2012-2020)
18
Patented Drug Market Forecast
19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Italy 2012-2020)
21
Generic Drugs Market Forecast
22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Italy 2012-2020)
24
OTC Medicines Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Italy 2012-2020)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Italy 2014-2020)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Italy 2014-2020)
28
Industry Risk Reward Index
29
Western Europe Risk/Reward Index
29
Italy Risk/Reward Index
35
Rewards
35
Risks
35
Regulatory Review
36
Intellectual Property Issues
37
Pricing Regime
38
Reimbursement Regime
42
Market Overview
46
Healthcare Sector
46
Table: Healthcare Resources (Italy 2010-2015)
49
Table: Healthcare Personnel (Italy 2010-2015)
49
Table: Healthcare Activity (Italy 2010-2015)
50
Research & Development
50
Clinical Trials
51
Epidemiology
52
Competitive Landscape
54
Research-Based Industry
54
Table: Multinational Market Activity
55
Pharmaceutical Distribution
55
Pharmaceutical Retail Sector
56
Company Profile
58
GlaxoSmithKline
58
Menarini
60
Novartis
63
Pfizer
66
Recordati
68
Demographic Forecast
71
Table: Population Headline Indicators (Italy 1990-2025)
72
Table: Key Population Ratios (Italy 1990-2025)
72
Table: Urban/Rural Population & Life Expectancy (Italy 1990-2025)
73
Table: Population By Age Group (Italy 1990-2025)
73
Table: Population By Age Group % (Italy 1990-2025)
74
Glossary
76
Methodology
78
Pharmaceutical Expenditure Forecast Model
78
Healthcare Expenditure Forecast Model
78
Notes On Methodology
79
Risk/Reward Index Methodology
80
Index Overview
81
Table: Pharmaceutical Risk/Reward Index Indicators
81
Indicator Weightings
82

The Italy Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Italy Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Italy pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Italy, to test other views - a key input for successful budgeting and strategic business planning in the Italian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Italian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Italy.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.